Addition of bevacizumab to conventional therapy improved progression-free survival in HER2-positive breast cancer

December 8, 2011 in Cancer

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant.

Luca Gianni, M.D., director of at the San Raffaele Cancer Center in Milano, Italy, presented results from AVEREL, a randomized, phase 3 trial, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011. The trial is designed to evaluate bevacizumab combined with trastuzumab and as first-line therapy for HER2-positive, locally recurrent/metastatic breast cancer. The study is the first randomized trial of bevacizumab in this type of breast cancer, according to the researchers.

Patients had measurable or evaluable HER2-positive, locally recurrent/ and Eastern Cooperative Oncology Group performance status 0/1 and had not received prior chemotherapy for advanced disease. Patients with metastases were excluded.

Researchers enrolled 424 patients from 60 centers during September 2006 to February 2010, with 421 patients receiving treatment. They randomly assigned patients to receive trastuzumab and docetaxel (n=208) or to receive trastuzumab and docetaxel plus bevacizumab (n=216).

At a median follow-up of 26 months, investigator assessment revealed an 18 percent reduction in risk of progression or death with the addition of bevacizumab compared with that of patients who received only trastuzumab and docetaxel. However, an independent review committee analysis found a 28 percent reduction in risk for progression or death with the addition of bevacizumab. Overall, median progression-free survival increased by 2.8 and 2.9 months with bevacizumab according to investigator analysis and independent review committee analysis, respectively.

Gianni said that because there are effective treatments for women with HER2-positive , researchers are now examining the precise role of an anti-angiogenic drug in combination with existing therapy.

"The concept of this trial was a test for the benefit observed in early phase 1 and phase 2," Gianni said. "In a way, we confirmed that combining an anti-angiogenic and [other treatment] is a good idea. But now, we have to search the subset of women who have the characteristics associated with benefit from addition of an anti-angiogenic. The key element is looking for a restricted indication that might have a longer-lasting effect than we can observe in AVEREL."

Biomarkers will be important in helping determine the best role for bevacizumab in treating HER2-positive cases, he said.

"The limit in anti-angiogenic therapy is that we treat all participants and we have no hint of what are the tumor characteristics or the patient characteristics that deserve intervention with anti-angiogenic therapy," Gianni said. "We have started some study investigation of biomarkers, and we hope that the AVEREL results, together with other studies, can help in finding ways of restricting indication of to those who could have the right benefit."

Provided by American Association for Cancer Research search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Research identifies a way to make cancer cells more responsive to chemotherapy

Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...

Cancer created 7 hours ago | popularity 5 / 5 (2) | comments 0

Mayo Clinic genomic analysis lends insight to prostate cancer

Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...

Cancer created 7 hours ago | popularity not rated yet | comments 0

When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs

Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...

Cancer created 8 hours ago | popularity not rated yet | comments 0 | with audio podcast

Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...

Cancer created 12 hours ago | popularity not rated yet | comments 0

Protein preps cells to survive stress of cancer growth and chemotherapy

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

Cancer created 13 hours ago | popularity not rated yet | comments 0 | with audio podcast


Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

ACP issues recommendations for management of high blood glucose in hospitalized patients

High blood glucose is associated with poor outcomes in hospitalized patients, and use of intensive insulin therapy (IIT) to control hyperglycemia is a common practice in hospitals. But the recent evidence does not show a ...

Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Scientists discover molecule triggers sensation of itch

Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...

Researchers find common childhood asthma unconnected to allergens or inflammation

Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...